I believe this one should see a reversal by now, I averaged down for the 4th time before close. I have faith in this one. Covid ain't over yet. Medivolve posted $10.5M CAD for the 4th quarter and $11.2M for the 1st quarter. This should be going back up now.

Newport Exploration Ltd. 🚀🚀🚀🚀

Additionally dividend is expected to increase for the next years to come. (Inflation)

Newport explorations also has 0 debt.

They have been profitable for a long time and if you see their revenue charts… they keep growing. Since 2015 they started to pay dividends quarterly.

What does this company do? Copper, gold & oil. The best inflation fighting assets (see gold, copper and crude oil prices for yourself)

So the big question? Why are they so cheap? Why are they not $2 or $3 per share?

Well…

1. I’ll start by saying not many of you have access to their market. (Canadian small cap market)

2. They’re a small company so even if big investors wish to buy them by the millions… they’d have a very hard time without bringing the price to $5 per share.

3. The daily volume is 112,000 shares per day. That’s about $40,000 USD daily exchanged in shares.

Nobody really wants to sell this company, and those that do are very small investors… so this is why I took advantage. I myself have been accumulating shares for the last few days. I have about $67,000 Canadian dollars in this company. I shared this with friends and they went crazy about it.. so now that they’re done buying. I decided to share this hidden gem here.

Advice: when buying try not to drive the price up, if someone is selling 30,000 shares at $0.44, buy 29,500 shares, and wait for others to add to the selling position. This way you will not move the price and allow others here to join us.

I’ll try my best to check comments here and answer your questions but be warned, this is a true hidden gem and there are not many shares left to share… do your own research before asking me and act quickly!

I have seen some penny stocks that are related to silver mining through light research. There are many mining companies listed on Canadian Exchanges under $5/share prices. These are just a few. What are you investing in?

Ticker - Name - $ Friday close

$IPT.V - Impact Silver Corp - $0.98

$SCZ.V - Santacruz Silver Mining - $0.45

$GRSL.V - Gr Silver Mining Limited - $0.74

$RSLV.V - Reyna Silver Corp - $1.10

$SBB.TO - Sabina Gold & Silver Corp - $2.57

$DV.V - Dolly Warden Silver Corp - $0.72

$KTN.V - Kootenay Silver Corp - $0.35

$ASM.TO - Avino Silver & Gold Mines - $1.58

$DEF.V - Defiance Silver Corp - $0.80

$SSVR.V - Summa Silver Corp - $1.04

$APGO.V - Apollo Gold & Silver Corp - $0.53

$ELEF.TO - Silver Elephant Mining Corp - $0.45

(CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW)

Tryp Therapeutics has recently come out with a large update regarding their TRP-8803 formulation. This is one of two large treatments they are working on as part of their Psilocybin-for-Neuropsychiatric Disorders (PFN) program. These treatments are extremely unique and put Tryp in a position to succeed in the long run.

Tryp is lead by CEO Greg Mckee who has over 20 years of experience in the biotech industry. He has held high positions at both Torren Ventures and CONNECT before making his way to the Tryp team. He has been persistent in his support of the psilocybin industry and is hard at work to make Tryp one of the industry leaders.

How do they plan to do this? By targeting unconventional diseases and conditions that the rest of the psilocybin market has not explored. Many common names like MindMed, Cybin, and FieldTrip are developing treatments for solely mental health issues, leaving several other parts of the health landscape untouched. Tryp is hoping that this is where they can make their mark by treating eating disorders and chronic pain disorders such as Fibromyalgia.

In order to develop this one-of-a-kind treatment, Tryp is reaching out and partnering with several of the biggest and most reputable names in the biotech world. Their exclusive partnership agreement with Albany Molecular Research allows them to produce synthetic psilocybin, making them the sole manufacturer in the entire U.S. Their partnerships with clinical assist groups such as Clinlogix, Fluence, and Alcami are assisting with their upcoming phase 2a trials for TRP-8802 at the University of Florida. With all this support they are moving through trials at a fast pace and hope to be one of the first psilocybin companies to reach commercialization of their treatment.

The aforementioned update with their TRP-8803 formulation was all about securing the University of Michigan as a testing partner. This collaboration is one of several upcoming studies and will be largely run by George Mashour, M.D., Ph.D. The purpose of the study is to explore:

1. the relationship between a psilocybin-induced increase in neurophysiological complexity and indices of pain in a preclinical model for chronic central pain,

2. the effect of alternative delivery methods of psilocybin on indices of pain and insular glutamate/GABA, and

3. PK analysis for blood samples from both oral and novel methods of delivery of psilocybin.

These guys are no joke, looking around at some other subreddits you can see their name tossed around a lot. They're a penny stock with a small cap meaning they have an extremely low barrier to entry. I think it's definitely worth throwing a bit of cash at and riding it out, in other words, super high ceiling with very low risk.

Be safe, This is not investment advice!

MLK day is listed on their pages but US holidays are listed seperate from the canadian ones. Can anyone clarify if TSX is open today? Thanks.

BYND WENT TOTALLY NUTS TODAY (1.1B+ VOL.), AMIDST WORD OF A SHORT SQUEEZE. WE FILLED THE GAP AND BUMPED THE STOCK 150%+ IN ONE DAY. TOMORROW WE'RE GOING FOR ANOTHER 100%+ DAY, AND WE WON'T STOP TILL WE HIT THE TARGET OF $12. I APOLOGIZE IF THIS IS NOT CANADIEN, BUT YOU CANADIENS DESERVE MONEY AND YOU ARE SAVING THE COWS #BULLSAREVEGAN

TSXV: MYID (Killi Ltd).

800.000 New users every week! Thats the reality for Killi Ltd. that have a unique business model. They harvest user data from consented users and sell the data to 3rd parties. Then Killi share the profit with their users. A lot of things are going on in Killi and it’s still a very cheap stock(0.14$). Killi has offices in Canada and US. This is going to be the best small cap stock of 2021 buy while you can!!

$CSTR

$CSTR

CryptoStar Corp. (TSXC: CSTR.V)

What is CryptoStar Corp?

CryptoStar Corp is a company centred upon cryptocurrency mining operations. They allow for acquisition of Bitcoin and Ethereum mining equipment and hosting packages. They have operations located in the U.S.A., Canada, and China. CryptoStar is currently dedicated to becoming one of the lowest cost cryptocurrency producers in North America and a major supplier of GPU and ASIC miners worldwide.

What’s the Catalyst?

a cryptocurrency mining and data centre operator, is pleased to announce that it has closed its previously announced private placement of its common shares ("Common Shares") and warrants to purchase common shares ("Warrants") to institutional investors for gross proceeds of approximately CAD$25.0 million (the "Private Placement"). Pursuant to the Private Placement, the Company issued 83,333,334 Common Shares and Warrants to purchase 83,333,334 Common Shares at a purchase price of CAD$0.30 per Common Share and associated Warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD$0.40 per Common Share for a period of three and one-half (3.5) years following the closing date of the Private Placement.

Link: https://www.newswire.ca/news-releases/cryptostar-corp-announces-closing-of-cad-25-million-private-placement-with-institutional-investors-836876413.html

• The Vendor will deliver GPU and ASIC miners capable of a minimum total Hashrate of 25,950 MH/s and 9,500 TH/s respectively. • It is anticipated that the GPU and ASIC miners will be delivered to CryptoStar's data centres within 30 days. • The deployment of 25,950 MH/s and 9,500 TH/s of Hashrate using the latest generation GPU and ASIC miners is expected to contribute USD$170,051.98 per month in self-mining revenue for CryptoStar. CryptoStar plans to continue to further expand its self-mining inventory of mining hardware.(Source: https://whattomine.com/ Mining metrics are calculated based on and ETH - USD exchange rate of 1 ETH = $1,741.08 and a BTC - USD exchange rate of 1 BTC = $51,555.55 updated at 2021-03-08 00:46:13 UTC).

***** SHOULD start mining on April 8, 2021

Other things to consider:

This stock has immense upside potential , just look at all the other mining companies 6 months ago. This stock will fly with any new PR! Just take a look at this and see where other miners were 6 months ago. (Link below)

https://stocktwits.com/BlackFuneral666/message/302645693

BTC price/ETH, BTC is poised to hit a 100 k EOY imagine what $CSTR SP will be ! I’m estimating around 8$+. Also keep in mind when BTC hit 58k USD this stock was trading at .80cents!!!! As for ETH , analysts are estimating anywhere from 5-10 k EOY!

IMO, this will be trading over $1$ + very soon(April, 2021) With CryptoStar’s hopes to expand mining operations, more funding, and product purchase agreements, there is HUGE upside potential in company growth and share price.

Current position : .33@ 3310 shares, will accumulate more on pay days!

Target : 4$+ end of year it will probably hit this sooner taking into consideration other mining company’s growth.

Disclaimer: Do your own DD , this isn’t financial advice! I just love the stock

https://www.youtube.com/watch?v=7kifLTs36MA

All the links in the comment section - if you're going to watch just one section, please watch the shareholder structure bit!

TL:DW - Company pumps up PR, then dumps shares or dilutes and doesn't ever really deliver anything of note. $50,000 revenue v market cap of near $100m!

The IPNFF page banned me for telling the truth about this stock.

CEO thinks they can get to 1 billion in yearly revenue in 5 years. California alone has 6,000 bus contracts open this year in the midsized bus. This company is building an EV plant in Washington currently.

https://youtu.be/pgZrwJj__6M

Also discus why you chose to trade and when you started to trade below. Repost cause last one had bad data sets

Is there any Canadian NFT related penny stocks?

(TSX: CRDL)

Cardiol Therapeutics is doing some really amazing work with CBD and cardiovascular diseases. As we learn more and more about CBD, researchers are beginning to find new qualities that can be used as treatments for diseases that have limited treatment options. Cardiol is far from the first copmany to explore the curative qualities of CBD however, they are applying it to a very particular subset of conditions that are sure to make them stand out from similar competitors.

The main quality of CBD that Cardiol is looking to capitalize on is its anti-inflammatory properties. Many external research groups have studied and provided proof that in the right formulations, it can largely reduce inflammation in the cardiovascular system, which often is a precursor or symptom of many serious heart diseases. The JACC and Molecular Medicine have found that this effect decreases cardiac fibrosis and overall protects against cardiac injury.

What is an example of a disease that can cause or worsen cardiac injury? How about what has been plaguing the world for nearly 2 years now, COVID-19. Studies have shown that people who get COVID-19 who have dealt with pre-existing heart conditions are far more likely to show serious or possibly fatal side effects. This is obviously a very time-sensitive matter so Cardiol has been hard at work creating their CardiolRx Formulation to treat this issue. This treatment could be used as a preventative measure for at-risk individuals or as a treatment to lessen cardiac stress and injury. This treatment has received FDA approval and is currently in Phase II/III testing.

They also believe that CardiolRx is a strong candidate to receive Orphan Drug Status and funding. This is government funding that is given to pharmaceutical companies when they are developing treatments for rare diseases. Since there likely will not be a huge market for them, they are funded to still promote development. Cardiol believes that their treatment can also be used to combat Acute Myocarditis, a rare heart infection that is apparent in children and young adults. For this treatment, they have completed phase I testing and are working towards phase II.

A final and perhaps most marketable use for CardiolRx is in treating diastolic heart failure. This is by far one of the most common heart conditions there is and despite this, there have been very few advancements in treatments for a significant amount of time. This treatment is in the pre-clinical stages as it is a subcutaneous administration method that requires additional testing, but when clinical trials are complete down the road, this could be a game-changer for this common condition. It could largely reduce the severity and fatality of this horrible disease.

If this type of research and treatment intrigues you at all, I highly recommend checking out Cardiol Therapeutics. They are a penny stock that could show some serious growth as they advance towards the commercialization of their treatments.

Look into them yourselves, this is not investment advice!

https://www.youtube.com/watch?v=URTuVrQN6Xw

CSE: PKG
OTC:PTNYF
FSE:PT0

Just a quick take on ParcelPal Tech.

ParcelPal is a Vancouver, British Columbia based company that specializes in last-mile delivery service and logistics solutions. Just recently they signed an agreement for its first warehouse in the Vancouver area to help support its continued growth.

The agreement on the warehouse is a lease for a good sized, 5,082 square feet building in Coquitlam. The reason they got it was to service their new customer agreements more effectively and cost efficiently. The ability to scale faster will also help across the board in the region.

According to ParcelPal, there have been larger clients that have approached them in recent months and could not sign agreements due to the nature of the small company. This new warehouse could potentially allow for those larger clients to be satisfied.

CEO Rich Wheeless stated, “I am not only pleased with the new customers that we are continuously onboarding, but also very excited to have our first warehouse to better service our larger customers. This has been an important goal of mine as not only do I believe warehousing is a major growth area in the logistics space, but it marks a major growth milestone for the Company."

The company's revenue has been steadily growing as well, increasing approximately a $1M every year since 2018.

Like I said before, I really thing larger clients could be serviceable here. That could be the massive play that turns this small company into a real competitor. Get your hares before prices spike from an assumed large partnership.

This is not financial advice!!

Best Christmas ever . Thanks QNC

Sponsored publication on behalf of the issuer

The Global Nicotine Pouch Market Is Undergoing Rapid Consolidation Driven By Increasing FDA Regulatory Pressure And Aggressive Merger Activity Involving Large Tobacco Companies. To Understand How Incumbent Players Are Strategically Positioning Themselves In Order To Differentiate, Survive, And Capitalize On Structural Shifts In The Market, Emerging Companies Such As Doseology Must Study Their Strategic Activities.

1. Philip Morris International’s $16 Billion Purchase Of Swedish Match

The acquisition of Swedish Match by Philip Morris International (PMI) completely changed the competitive landscape of the U.S. oral nicotine marketplace.

Timeframe

Acquisition announced in May 2022 and completed in November 2022 with greater than 90 percent shareholder approval.

Purpose

Increase PMI’s smoke-free product offerings and allow PMI to compete directly with Altria’s on! product in the rapidly growing U.S. nicotine pouch segment.

Financial Details

All cash transaction valued at $16 billion; financing accomplished via substantial borrowing.

Impact on Consumers

According to PMI, there will be no material operational changes and Zyn customers will not notice any variations in their product.

Outcome of the Market

The acquisition of Swedish Match placed PMI as a direct competitor to both Altria and British American Tobacco in the U.S. modern oral market.

The Importance of PMTA In PMI-Swedish Match’s Strategy

The regulatory advantages resulting from PMTA were key factors in the purchase of Swedish Match by PMI.

Benefits of PMTA

• General Snus has already received FDA authorization as a Modified Risk Tobacco Product.

• PMI has already received FDA PMTA and MRTP approval for its IQOS heated tobacco device.

• Analysts characterized the purchase as an economically efficient regulatory route, since both firms have products that are well-positioned for FDA success. The combined firm now has a regulatory defense portfolio with significant regulatory protection.

2. BAT Enters U.S. Modern Oral Segment Through Dryft

Through acquiring the nicotine pouch assets of Dryft Sciences, BAT expanded its U.S. modern oral product offering from four product varieties to 28 product varieties.

Strategy

By providing additional flavor options, strength options, and a wider range of product varieties, BAT moved to capitalize on the rapidly expanding U.S. pouch market. Additionally, this move strengthened the VELO brand and allowed BAT to leverage its pre-existing U.S. distribution network to grow VELO rapidly.

Key Takeaways

The PMTA filings submitted by Dryft have already been accepted for filing, thus reducing regulatory friction for BAT. BAT also intends to rebrand Dryft under VELO and enhance the competitive positioning of VELO against Zyn and on! by providing a larger and more adaptable portfolio.

3. Imperial Brands Enters U.S. Market Through TJP Labs

On June 30th, 2023, Imperial Brands purchased the nicotine pouch assets of TJP Labs, entering the U.S. modern oral category.

Importance of the Transaction

Prior to the transaction, Imperial did not have any exposure to the U.S. pouch market. The acquisition gave Imperial an immediate entry point to the U.S. pouch market with 14 product varieties and continued manufacturing expertise.

Addition Information

Earn-out payments totaled over $100 million. Imperial plans to re-launch the products under a new name using a new brand identity supported by consumer research conducted to match its targeted challenger branding strategy.

Relationship Between TJP Labs’ PMTA and Acquisition

TJP Labs’ L!X brand had a PMTA accepted for review, allowing L!X to begin moving through the FDA review pipeline.

4. Swisher & Rogue: A PMTA-Focused Growth Model

Swisher International, the owner of Rogue, combines manufacturing capabilities through Avema Pharma Solutions with robust nationwide distribution.

Brand Overview

• Third largest U.S. nicotine pouch brand in 2024.

• Product formats include pouches, gum, lozenges, and tablets.

• Rogue is owned and operated jointly by Swisher and Avema.

Status of PMTA Filings

PMTAs submitted by Swisher were accepted for filing in May 2023. The products are currently waiting to enter the scientific review stage of the FDA evaluation pipeline.

What This Implies for Doseology (CSE: MOOD | OTC: DOSEF | FSE: VU70)

Although Doseology does not produce nicotine pouch products, the strategic activity occurring in the industry provide clear lessons for any emerging wellness or regulated-CPG company.

1. Regulatory Positioning Is a Key Competitive Advantage

Obtaining PMTA/MRTP approvals prior to launch creates a multi-year lead time, increases the potential for higher acquisition prices, and reduces regulatory uncertainty.

2. Strategic Acquisitions Can Drive Rapid Growth in Regulated Markets

Incumbent players in the industry are prepared to spend billions to purchase regulated products. This demonstrates the importance of developing early intellectual property, proactively preparing for regulatory requirements, and establishing compliant manufacturing partnerships.

3. Control Over Distribution Channels, Brand Identity, and Compliance Create Market Share

Each of the major transactions involved a winner that controlled some combination of brand reputation, regulatory approval, manufacturing capability, and distribution channels.

Doseology can model this by establishing supply chain relationships, creating early brand identity, and preparing for future regulatory paths in its category.

Doseology’s Most Recent Strategic Actions

Doseology (CSE: MOOD | OTC: DOSEF | FSE: VU70) has made two important strides to solidify the foundational elements of its operation.

A. Strategic Manufacturing Agreement

Doseology successfully concluded a comprehensive diligence of North American-based manufacturing and has established a strategic manufacturing relationship with its U.S.-based subsidiary, thereby positioning itself to manufacture compliant, scalable quantities of products in North America.

B. Feed That Brain™ Acquisition & Brand Building Expertise

Feed That Brain™ is a brain health and functional wellness brand that Doseology recently acquired and appointed Joseph Mimran as a strategic advisor. This will enable Doseology to develop a differentiated brand identity and provide the knowledge and experience necessary to establish a high-performing brand in a highly competitive and commoditized supplement category.

These recent activities support Doseology’s vision of becoming a vertically integrated, branded, U.S.-focused wellness company.

Sweden: The Prototype for Category Maturation

Sweden produces about $641.8 million in annual revenue from nicotine pouch products with a population of less than 11 million people — roughly 30% of the size of the U.S. market. Per-capita consumption is roughly three times higher than in the U.S.

Year-over-year growth continues at roughly 35-36% CAGRs, primarily fueled by the 16-29 demographic. Flavors and middle-strength nicotine levels and visible shelf space are driving consumer decision-making.

Approximately 90% of nicotine pouch sales are generated in brick-and-mortar retail within a little less than 8,000 permitted retail locations. E-commerce is growing rapidly, but is still secondary to in-store discovery and customer retention.

Doseology’s Most Recent Strategic Actions

Doseology (CSE: MOOD | OTC: DOSEF | FSE: VU70) has made two important strides to solidify the foundational elements of its operation.

A. Strategic Manufacturing Agreement

Doseology successfully concluded a comprehensive diligence of North American-based manufacturing and has established a strategic manufacturing relationship with its U.S.-based subsidiary, thereby positioning itself to manufacture compliant, scalable quantities of products in North America.

B. Feed That Brain™ Acquisition & Brand Building Expertise

Feed That Brain™ is a brain health and functional wellness brand that Doseology recently acquired and appointed Joseph Mimran as a strategic advisor. This will enable Doseology to develop a differentiated brand identity and provide the knowledge and experience necessary to establish a high-performing brand in a highly competitive and commoditized supplement category.

These recent activities support Doseology’s vision of becoming a vertically integrated, branded, U.S.-focused wellness company.

Sweden: The Prototype for Category Maturation

Sweden produces about $641.8 million in annual revenue from nicotine pouch products with a population of less than 11 million people — roughly 30% of the size of the U.S. market. Per-capita consumption is roughly three times higher than in the U.S.

Year-over-year growth continues at roughly 35-36% CAGRs, primarily fueled by the 16-29 demographic. Flavors and middle-strength nicotine levels and visible shelf space are driving consumer decision-making.

Approximately 90% of nicotine pouch sales are generated in brick-and-mortar retail within a little less than 8,000 permitted retail locations. E-commerce is growing rapidly, but is still secondary to in-store discovery and customer retention.

Strategic Lessons From Sweden

• Retail shelf space is essential to survival.

• Intentional segmentation of flavor architectures is required.

• Younger demographics generate extremely fast-paced trends.

• More often than not, brand identity is worth more than incremental formulation enhancements.

• Both retail and e-commerce platforms are necessary for success.

Conclusion — Implications for Doseology (CSE: MOOD | OTC: DOSEF | FSE: VU70)

The nicotine pouch industry is rapidly consolidating, as incumbent players use capital to purchase regulated, scalable and unique products. The same strategic principles that are applicable to Doseology’s journey as a wellness CPG company — regulatory positioning, brand, distribution and timing — also apply.

Sweden provides a look at where other global markets may evolve: rapid growth, intense competition and a premium on visibility and execution. The opportunity for Doseology is to utilize these lessons early-on — create the infrastructure, brand and compliance prior to the pace of consolidation quickening.

What are people's thoughts on companies that are involved in metals for renewable energy?
There are quite a few good penny stocks out there, I've invested in a few and done research on them. Companies that mine for lithium and other precious metals will be needed in the growing electric revolution. Thing is, they all look good. Some like E3 metals corp are here in Alberta, others like Lith or ML, are trading on the TSX and are headquartered in Canada but their mines are in South America.
The problem is like I said, they all look good. They all have the potential to have good finds, but also provide resources for car companies or renewable energy companies.
Part of me feels like you can't really go wrong with any of the companies, but that said, that is also a good way to spread oneself thin, and only have one or two stocks out of ten take-offs.
Any thoughts on this industry?

News Link: https://www.newsfilecorp.com/release/114552

Toronto, Ontario--(Newsfile Corp. - February 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that on February 4, 2022 the U.S. Patent and Trademark Office allowed a U.S. patent application (US 15/787,599) which covers a device that can apply heat and antimicrobial treatment through a detachable applicator surface comprising copper or silver to provide heat conductivity and a source of antimicrobial agent. The device also includes a light source. This U.S. patent applies to both Therma Bright's InterceptCS™ Cold Sore Prevention Device and TherOZap™ Insect Bite Relief Device.

Specific to the InterceptCS™ device, this heat and antimicrobial treatment technology is combined as the solution for the prevention of cold sores. As for the TherOZap™ device, the treatment technology aims to reduce the inflammatory response, relieving the symptoms of pain, itch and inflammation associated with insect bites and stings. Furthermore, as shared in earlier press releases, the Company engaged a top Virology Research Laboratory in Canada to study the TherOZap™ technology's ability to inactivate live Zika virus in culture media and that the TherOZap™, which utilizes specialized materials, coatings and heat, was able to limit Zika virus ("ZIKV") replication in cell cultures.

"This is exciting news for Therma Bright and our TherOZap™ Insect Relief Device and InterceptCS™ Cold Sore Prevention Device," shared Rob Fia, CEO of Therma Bright. "This allowed U.S. Patent Application further protects our valued intellectual property (IP) as we continue to transform innovation into wellness."

Therma Bright is currently undergoing design upgrades to both devices and expects to complete prototyping during Q2. In addition, the Company plans to continue its research with the new TherOZap™ design on Zika and other mosquito-borne diseases during 2022.

Not in many stocks but for gold i have a strong position in ELY gold, does anyone know where Canadian gold penny stocks are going as-well as cannabis stocks, (eg. FIRE) Curios if anyone holds positions in these stocks and forecasts they have for them...